{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-25-037076","form_type":"8-K","ticker":"PRME","cik":"0001894562","company_name":"Prime Medicine, Inc.","filed_at":"2025-07-31T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.536855+00:00","generated_at":"2026-05-17T22:28:29.729728+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Prime Medicine prices $125M equity offering; net proceeds ~$120.2M for R&D","bullets":["Offering of 38M shares at $3.30/share; underwriters have 30-day option for 5.7M additional shares.","Estimated net proceeds of $120.2M after underwriting discounts and expenses.","Proceeds to fund Wilson's Disease and Alpha-1 Antitrypsin Deficiency programs; remainder for working capital.","Underwriting led by TD Securities and BMO Capital Markets; expected close August 1, 2025.","Cystic Fibrosis Foundation to purchase 1,818,181 shares without any underwriting discounts."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-25-037076","json":"https://secwatch.observer/filing/0001628280-25-037076.json","markdown":"https://secwatch.observer/filing/0001628280-25-037076.md","text":"https://secwatch.observer/filing/0001628280-25-037076.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1894562/000162828025037076/0001628280-25-037076-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1894562/000162828025037076/prme-20250730.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T22:28:29.729728+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}